Nephrotoxicities of antineoplastic and immunosuppressive agents.
D000470:Alkaloids / Q000009:adverse effects; D000477:Alkylating Agents / Q000009:adverse effects; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects; D000963:Antimetabolites / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D003524:Cyclosporins / Q000009:adverse effects; D004285:Dogs; D005260:Female; D000882:Haplorhini; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007668:Kidney / Q000187:drug effects* / Q000473:pathology; D007674:Kidney Diseases / Q000139:chemically induced*; D008297:Male; D051379:Mice; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000009:adverse effects; D013311:Streptozocin / Q000009:adverse effects; D013713:Teniposide / Q000009:adverse effects
D000470:Alkaloids; D000477:Alkylating Agents; D000903:Antibiotics, Antineoplastic; D000963:Antimetabolites; D000970:Antineoplastic Agents; D003524:Cyclosporins; D007166:Immunosuppressive Agents; D009607:Nitrosourea Compounds; D013311:Streptozocin; D013713:Teniposide